

Prediction of small cell lung cancer in the Lambert-Eaton myasthenic syndrome

Titulaer, M.J.

Citation

Titulaer, M. J. (2010, November 24). *Prediction of small cell lung cancer in the Lambert-Eaton myasthenic syndrome*. Department of Neurology, Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University. Retrieved from https://hdl.handle.net/1887/16174

Version: Corrected Publisher's Version

License: License agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/16174

Note: To cite this publication please use the final published version (if applicable).

List of publications

Papers from this dissertation

Titulaer MJ*, Klooster R*, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A, Sillevis Smitt PAE, Van der Maarel SM, Verschuuren JJGM. SOX antibodies in small cell lung cancer and Lambert-Eaton myasthenic syndrome - frequency and relation with survival. *J Clin Oncol 2009 Sep* 10;27(26):4260-7

Titulaer MJ, Wirtz PW, Willems LNA, van Kralingen KW, Sillevis Smitt PAE, Verschuuren JJGM. Screening for Small-Cell Lung Cancer: A Follow-Up Study of 100 Patients With Lambert-Eaton Myasthenic Syndrome. *J Clin Oncol 2008 Sep* 10;26(26):4276-81

Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, de Visser M, Sillevis Smitt PA, Verschuuren JJ. The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients. *J Neuroimmunol* 2008 Sep 15;201-202:153-8

Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. *Ann N Y Acad Sci 2008;1132:129-34*

Sabater L, **Titulaer M**, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert Eaton myasthenic syndrome. *Neurology* 2008 Mar 18;70(12):924-8

Titulaer MJ, Wirtz PW, Wintzen AR, Verschuuren JJ. Re: Lambert-Eaton myasthenic syndrome with pure ocular weakness. *Neurology 2008 Jan 1;70(1):86*

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM. EFNS Guidelines for the screening for tumours in paraneoplastic syndromes. *Eur J Neur accepted*

Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PAE, Kuks JBM, Roep BO, Vincent A, van der Maarel SM, van Dijk JG, Lang B, Verschuuren JJGM. The clinical DELTA-P score accurately predicts small cell lung cancer in the Lambert-Eaton myasthenic syndrome. *submitted*

Papers not described in this dissertation

Wirtz PW, **Titulaer MJ**, van Gerven JMA, Verschuuren JJGM. 3,4-Diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. *Expert Review of Clinical Immunology 2010 accepted*

Selman M, Niks E, **Titulaer MJ**, Verschuuren JJGM, Wuhrer M, Deelder A. IgG Fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis subtypes. *J Proteome Research 2010 accepted*

Wirtz PW, Verschuuren JJ, de Kam ML, Schoemaker RC, van Hasselt JGC, Tjaden UR, **Titulaer MJ**, den Hartigh J, van Dijk JG, van Gerven JMA. Efficacy of 3,4-diaminopyridine and pyridostigmine in the Lambert-Eaton myasthenic syndrome. *Clin Pharmacol Ther 2009 Jul;86(1):44-8*

Pellkofer HL, Armbruster L, Krumbholz M, **Titulaer MJ**, Verschuuren JJ, Schumm F, Voltz R Lambert-Eaton Myasthenic Syndrome: Differential reactivity of tumor versus non-tumor patients to subunits of the voltage gated calcium channel. *J Neuroimmunol 2008 Nov 15;204(1-2)136-9*

Verschuuren JJ, Wirtz PW, **Titulaer MJ**, Willems LN, van Gerven J. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. *Expert Opin Pharmacother 2006 Jul;7*(10):1323-36

Veldink JH, Kalmijn S, Groeneveld GJ, **Titulaer MJ**, Wokke JH, van den Berg LH. Physical activity and the association with sporadic ALS. *Neurology 2005 Jan 25;64(2):241-5*

Curriculum vitae

Maarten Jan Titulaer was born in Hengelo on August 1, 1977. After his graduation from secondary school (Gymnasium, Bataafse Kamp, Hengelo), he commenced his medical training at Utrecht university in 1995. In 1999, he participated in a research project concerning amyotrophic lateral sclerosis at the University Medical Centre (UMC) in Utrecht, supervised by Prof.dr. L.H. van den Berg. He obtained his master's degree at the Utrecht university in 2000. He performed a senior elective in neuromuscular disorders under the supervision of Prof.dr. J.H.J. Wokke at the UMC Utrecht, after which he obtained his medical degree in 2002. He started his training as a resident in Neurology at the department of Neurology, Leiden University Medical Center (head: Prof.dr. R.A.C. Roos). In 2005, he joined the neuromuscular research group to start the PhD project described (Prof.dr. J.J.G.M. Verschuuren, Dr. P.W. Wirtz), part of which was awarded with the Prinses Beatrix Fonds year price neuromuscular diseases 2008. He was allotted a residency award from the Dutch society for Clinical Neurophysiology (NVKNF) in 2007, for electromyographic research not described in this thesis. In 2009, he obtained a research fellowship from the European Neurological Society (ENS) to visit the Neurosciences group in Oxford, supervised by Prof.dr. A. Vincent and Dr. B. Lang. He was granted the 'Lijden for Leiden' award for neuromuscular research 2009. For his last part of his training, he worked as a clinical fellow at the Daniel den Hoed Clinic, Erasmus Medical Center in Rotterdam (head: Prof.dr. M.J. van den Bent).

From 2005 until 2010, he was a member of the board of the Dutch society of neurologists in training (VAAN). As a representative of the VAAN, he joined various committees of the Dutch society for Neurology (NVN). In his spare time, he likes to cycle his racing bike as well as to play the bassoon.

December 2010, he expects to qualify as a neurologist, after which he will continue his career at the University of Pennsylvania, Philadelphia (head: Prof.dr. J. Dalmau), granted by a clinical research fellowship by the Dutch Cancer Society (KWF Kankerbestrijding).